Sana Biotechnology (SANA) Operating Leases (2020 - 2026)
Sana Biotechnology (SANA) posted Operating Leases of $60.4 million for Q1 2026, down 5.43% sequentially from $63.9 million in Q4 2025, and down 22.81% YoY from $78.3 million in Q1 2025.
Sana Biotechnology (SANA) Operating Leases (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Operating Leases for 7 years, with the latest figure at $60.4 million in Q1 2026.
- Quarterly Operating Leases fell 22.81% year-over-year to $60.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.4 million (down 22.81% YoY) and the FY2025 annual result came in at $63.9 million, down 21.72% from the prior year.
- Operating Leases declined to $60.4 million in Q1 2026 per SANA's latest filing, from $63.9 million in the prior quarter.
- Over five years, Operating Leases peaked at $103.0 million in Q2 2022 and troughed at $60.4 million in Q1 2026.
- A 5-year average of $86.4 million and a median of $88.6 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2026: Operating Leases surged 55.65% in 2022, then fell 22.81% in 2026.
- Over 5 years, Operating Leases stood at $95.9 million in 2022, then slipped by 5.17% to $90.9 million in 2023, then slipped by 10.16% to $81.7 million in 2024, then declined by 21.72% to $63.9 million in 2025, then fell by 5.43% to $60.4 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $60.4 million, $63.9 million, and $67.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.23 Mn |
| Mar 31, 2026 | 60.45 Mn |
| Dec 31, 2025 | 63.92 Mn |
| Sep 30, 2025 | 67.87 Mn |
| Jun 30, 2025 | 71.66 Mn |
| Mar 31, 2025 | 78.31 Mn |
| Dec 31, 2024 | 81.66 Mn |
| Sep 30, 2024 | 85.48 Mn |
| Jun 30, 2024 | 88.56 Mn |
| Mar 31, 2024 | 92.92 Mn |
| Dec 31, 2023 | 90.90 Mn |
| Sep 30, 2023 | 83.37 Mn |
| Jun 30, 2023 | 100.25 Mn |
| Mar 31, 2023 | 101.61 Mn |
| Dec 31, 2022 | 95.86 Mn |
| Sep 30, 2022 | 99.86 Mn |
| Jun 30, 2022 | 102.96 Mn |
| Mar 31, 2022 | 102.52 Mn |
| Dec 31, 2021 | 101.78 Mn |
| Sep 30, 2021 | 92.40 Mn |